BiopharmaTrend.com

A fresh viewpoint on drug discovery, pharma, and biotech

Subscribe | Become an author | Author LogIn

Topic: ‘Pharmaceutical industry trends’


2018: AI Is Surging In Drug Discovery Market

   by Andrii Buvailo    7824
2018: AI Is Surging In Drug Discovery Market

Updated: 10.01.2019. Newly added content is marked in the text with "Update" sign.

The idea of using artificial intelligence (AI) to accelerate drug discovery process and boost a success rate of pharmaceutical research programs has inspired a surge of activity in this area over the last several years. In 2018, things are getting even “hotter” with the increase in the amount of partnerships, investments and other important events, summarized and grouped below into “mini-trends”.

Will 2019 Bring Positive Signals for the Declining Antibiotics R&D Market?

   by David Shlaes    193
Will 2019 Bring Positive Signals for the Declining Antibiotics R&D Market?

Antibiotic R&D has had a particularly bad year starting with The Medicines Company who abandoned their antibiotic R&D efforts and sold their antibiotic assets to Melinta late last year right after getting approval for vabomere. This year both Sanofi and Novartis abandoned their antibiotic R&D efforts and divested their clinical and preclinical assets. Allergan, holder of the North American rights to ceftaroline, dalbavancin and ceftazidime-avibactam, also announced that they would divest their antibiotic assets. I have not heard that they were successful. Achaogen has now undergone two efforts at “restructuring” involving virtually eliminating all R&D and has essentially put up the “for sale” sign just after achieving approval for plazomicin. Finally, Melinta abandoned their antibiotic R&D efforts in the face of miserable sales of their recently launched antibiotics including delafloxacin and vabomere.

Democratizing Artificial Intelligence For Pharmaceutical Research

   by Andrii Buvailo    384
Democratizing Artificial Intelligence For Pharmaceutical Research

Over the last five years the interest of pharmaceutical professionals towards machine learning (ML) and artificial intelligence (AI) has measurably increased -- while only one “AI-related” research collaboration involving “big pharma” appeared in the news in 2013, the number of such events increased up to 21 in 2017 alone, involving some of the top pharma players like GSK, Sanofi, Abbvie, Genentech, etc.

Get Ready For “Super-platforms” In Healthcare and Pharmaceutical Research

   by Andrii Buvailo    1098
Get Ready For “Super-platforms” In Healthcare and Pharmaceutical Research

What is a super-platform?

A “super-platform” is a term which describes a relatively new phenomenon in a modern technological world -- an online-to-offline (O2O) type of digital infrastructure, which spans across multiple sectors of economic activity providing a way for users (both businesses and consumers) to operate with multiple resources, products and services within a uniform, standardized, and highly interconnected way.

Imagine, you want to be able to search for information, shop online, pay for products and services, communicate with someone by email, or chat, create and manage text and spreadsheet documents, translate them into any language on the go, store and organize data like photos and videos, find local restaurants and get driving directions, or just entertain yourself by playing games -- and you prefer to have all of that in one place without needing to search for numerous websites and resources? You can do just that in your single Google account. This is what a super-platform does: it provides a way to conveniently engage in totally different types of activity across different sectors.